The Aimmune Therapeutics Inc. (AIMT) Insider Sold $420,000.00 in Stock

The Aimmune Therapeutics Inc. (AIMT) Insider Sold $420,000.00 in Stock

Aimmune Therapeutics Inc. (NASDAQ:AIMT) insider Mary M. Rozenman sold 25,000 shares of the firm’s stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $16.80, for a total transaction of $420,000.00. Following the transaction, the insider now directly owns 25,000 shares of the company’s stock, valued at approximately $420,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) opened at 16.55 on Friday. The stock’s 50 day moving average is $15.53 and its 200 day moving average is $13.65. The firm’s market capitalization is $699.30 million. Aimmune Therapeutics Inc. has a 52-week low of $9.77 and a 52-week high of $22.01.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Wednesday, August 10th. The company reported ($0.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.01. On average, equities research analysts forecast that Aimmune Therapeutics Inc. will post ($1.75) EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co. NY boosted its position in Aimmune Therapeutics by 9.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 9,617 shares of the company’s stock worth $130,000 after buying an additional 797 shares in the last quarter. Emerald Acquisition Ltd. bought a new position in Aimmune Therapeutics during the second quarter worth approximately $154,000. American International Group Inc. boosted its position in Aimmune Therapeutics by 135.7% in the second quarter. American International Group Inc. now owns 15,131 shares of the company’s stock worth $164,000 after buying an additional 8,711 shares in the last quarter. Nationwide Fund Advisors boosted its position in Aimmune Therapeutics by 127.7% in the second quarter. Nationwide Fund Advisors now owns 16,929 shares of the company’s stock worth $183,000 after buying an additional 9,495 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in Aimmune Therapeutics during the second quarter worth approximately $186,000. 68.87% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have recently issued reports on the stock. JMP Securities assumed coverage on shares of Aimmune Therapeutics in a research note on Monday, September 26th. They set an “outperform” rating and a $30.00 price target for the company. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $38.00 price target on shares of Aimmune Therapeutics in a research note on Friday, September 23rd. Wedbush reaffirmed an “outperform” rating and set a $42.00 price target on shares of Aimmune Therapeutics in a research note on Wednesday, September 21st. Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, September 19th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating and set a $35.00 price target on shares of Aimmune Therapeutics in a research note on Friday, August 19th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $32.20.

Aimmune Therapeutics Company Profile

Related posts

Leave a Comment